Traders should monitor upcoming topline data from PIVOT-006 and CORE-008 Cohort CX in 1H 2026, which could serve as key value inflection points. The expanded cash runway into 2029 reduces near-term dilution risk.
CGON drugs
CGON drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 27 $58.80entry
- T+1 · 9mo ago −1.77%α −1.82% · $57.76
- T+5 · 9mo ago +5.24%α +7.22% · $61.88
- T+20 · 8mo ago +9.90%α +17.45% · $64.62
- T+60 · 6mo ago +5.26%α −4.13% · $61.89
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CG Oncology reported financial results for Q4 and full year 2025, highlighting a cash position of $742.2 million as of December 31, 2025, with an increase to $903.0 million by February 26, 2026, due to ATM share sales. The company expects this cash to fund operations into the first half of 2029. Key upcoming catalysts include topline Phase 3 data from the PIVOT-006 trial in intermediate-risk NMIBC and Phase 2 combination data from CORE-008 Cohort CX, both expected in the first half of 2026.
Key Financial Metrics
Key Facts
- Cash, cash equivalents, and marketable securities were $742.2 million as of December 31, 2025, and increased to $903.0 million by February 26, 2026.
- Net loss attributable to common stockholders was $161.0 million for full year 2025, up from $88.0 million in 2024.
- R&D expenses increased to $116.6 million in 2025 from $82.1 million in 2024; G&A rose to $73.5 million from $33.7 million.
- Topline Phase 3 data from PIVOT-006 trial in intermediate-risk NMIBC expected in 1H 2026.
- First results from Phase 2 CORE-008 Cohort CX (cretostimogene + gemcitabine) in high-risk NMIBC expected in 1H 2026.
- BLA submission for HR BCG-unresponsive NMIBC planned for 2026.
Financial Impact
Cash increased by ~$160.8 million in Q4 2025 and early 2026 via ATM equity sales; net loss widened to $161.0 million in 2025 from $88.0 million in 2024.
Risk Factors
- Clinical trial results may not meet expectations, particularly in registrational trials like PIVOT-006.
- Increased operating expenses and widening net losses could pressure valuation if revenue milestones are delayed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3246513 |
Track record
25 reports on CGON
6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +26.33% at T+20 after the Jun 12, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 16, 2026today 8-K Bullish 7/10 Entry $98.84 Now $84.78 −14.23% settles Dec 15
- Nov 16, 2026today Press Release Bullish 7/10 Entry $95.01 Now $84.78 −10.77% settles Dec 15
- Nov 6, 202610d ago 8-K Bearish 5/10 Entry $75.99 Now $84.78 −11.57% settles Dec 7
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $75.99 Now $84.78 +11.57% settles Dec 7
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $64.06 Now $84.78 +32.34% settles Dec 2
- Oct 19, 202628d ago 3 Neutral 2/10 Entry $61.93 Now $84.78 +36.90% settles Nov 17
- Oct 15, 20264w ago 144 Neutral 2/10 Entry $59.85 to $74.40 Now $84.78 +41.65% ▲ +24.31% +25.47% vs SPY
- Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $63.13 to $74.74 Now $84.78 +34.29% ▲ +18.39% +21.66% vs SPY
- Aug 6, 202614w ago Press Release Bearish 7/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
- Aug 6, 202614w ago 424B5 Bearish 6/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers